Breaking Down SG&A Expenses: Alkermes plc vs Taro Pharmaceutical Industries Ltd.

SG&A Expenses: Alkermes vs. Taro - A Decade of Financial Insights

__timestampAlkermes plcTaro Pharmaceutical Industries Ltd.
Wednesday, January 1, 201419990500091733000
Thursday, January 1, 201531155800087644000
Friday, January 1, 201637413000092365000
Sunday, January 1, 201742157800085656000
Monday, January 1, 201852640800088196000
Tuesday, January 1, 201959944900089971000
Wednesday, January 1, 202053882700093413000
Friday, January 1, 202156097700091355000
Saturday, January 1, 2022605747000113676000
Sunday, January 1, 2023689751000198366000
Monday, January 1, 2024645238000218935000
Loading chart...

Data in motion

A Comparative Analysis of SG&A Expenses: Alkermes plc vs. Taro Pharmaceutical Industries Ltd.

In the ever-evolving pharmaceutical industry, understanding the financial dynamics of key players is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of Alkermes plc and Taro Pharmaceutical Industries Ltd. over the past decade. From 2014 to 2023, Alkermes plc has consistently outpaced Taro in SG&A spending, with a notable increase of approximately 245% from 2014 to 2023. In contrast, Taro's SG&A expenses grew by about 140% during the same period.

The data reveals a significant surge in Alkermes' expenses in 2023, reaching a peak, while Taro's expenses also saw a substantial rise. This trend highlights the strategic investments and operational costs that these companies are undertaking to maintain their competitive edge. However, the absence of data for Alkermes in 2024 suggests a potential shift or anomaly worth further investigation.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025